Compare KMX & IBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KMX | IBRX |
|---|---|---|
| Founded | 1993 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Retail-Auto Dealers and Gas Stations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.2B | 8.2B |
| IPO Year | 2002 | 2015 |
| Metric | KMX | IBRX |
|---|---|---|
| Price | $64.04 | $8.15 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 16 | 7 |
| Target Price | ★ $37.18 | $12.57 |
| AVG Volume (30 Days) | 2.0M | ★ 8.4M |
| Earning Date | 04-14-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 38.71 |
| EPS | ★ 1.31 | N/A |
| Revenue | ★ $25,881,131,000.00 | $113,288,000.00 |
| Revenue This Year | N/A | $88.59 |
| Revenue Next Year | $1.82 | $131.15 |
| P/E Ratio | $47.94 | ★ N/A |
| Revenue Growth | N/A | ★ 668.31 |
| 52 Week Low | $30.40 | $1.95 |
| 52 Week High | $63.15 | $12.43 |
| Indicator | KMX | IBRX |
|---|---|---|
| Relative Strength Index (RSI) | 67.44 | 52.25 |
| Support Level | $56.74 | $7.77 |
| Resistance Level | N/A | $8.21 |
| Average True Range (ATR) | 1.87 | 0.29 |
| MACD | 0.22 | 0.04 |
| Stochastic Oscillator | 91.64 | 54.38 |
CarMax sells, finances, and services used and new cars through a chain of over about 260 retail stores. It was formed in 1993 as a unit of Circuit City and spun off into an independent company in late 2002. Used-vehicle sales were 80% of fiscal 2026 revenue and wholesale about 17%, with the remaining portion composed of extended service plans and repair. In fiscal 2026, the company retailed and wholesaled 780,684 and 538,203 used vehicles, respectively. CarMax is the largest used-vehicle retailer in the US, but still estimates that it had only about 3.6% US market share of vehicles zero to 10 years old in calendar 2025. CarMax is based in Richmond, Virginia.
ImmunityBio Inc is a biotechnology company focused on developing and commercializing next-generation immunotherapies designed to activate the patient's immune system and provide durable protection against cancer and infectious diseases. Its approach harnesses both the adaptive and innate immune systems with the Cancer BioShield platform. The platform is built around the proprietary IL-15 superagonist ANKTIVA (nogapendekin alfa inbakicept) and is supported by a portfolio that includes adenovirus-vectored vaccines, NK-cell therapies, and additional immunomodulators. The company operates in the United States and Europe, with the majority of its revenue coming from the United States.